Adrenal involvement in the course of malignant lymphoma occurs in about 4% of patients, but primary adrenal lymphoma (PAL) is extremely rare. To the best of our knowledge, only one case study reported the combination of PAL with pheochromocytoma. In the current study, we present the second case who was a 63-year-old man admitted to our hospital with hematuria and abdominal discomfort. Ultrasound imaging indicated the presence of a lesion, 5×4×3 cm in size, in the upper pole of his right kidney. Histopathologic study confirmed a collision tumor composed of pheochromocytoma and diffuse large B-cell lymphoma (DLBCL).
INTRODUCTION
Primary lymphomas of endocrine glands are extremely rare and usually involve thyroid gland and less commonly adrenal glands 1 . Pheochromocytomas as the neoplastic transformation of chromaffin cells of sympatoadrenal system are also rare and usually pure neoplasms [2] [3] [4] . Coexistence of PAL and pehochromocytoma is very rare and we describe a unique presentation of this association 5 .
Case presentation
A 63-year-old man with three different episodes of renal colic and painful hematuria was referred to our hospital. He had no specific medical history or hormonal symptoms. Physical examination was unremarkable and he had normal vital signs. In paraclinical investigations, ultrasound imaging revealed a mass in upper pole of right kidney. Pheochromocytoma workup was negative. The patient underwent right adrenalectomy. The submitted sample for pathologic study consisted of multiple fragmented irregular tumoral tissues, weighting 95 gram measuring totally 5×4×3 cm. The lymphoma part of our case was DLBCL which can arise in almost any part of the body and the first manifestation of this cancer is typically a rapidly growing mass, sometimes associated with B symptoms-fever, weight loss, and night sweats 13 . Our case showed none of the above-mentioned symptoms. On the other hand, one of primary adrenal tumors that can be seen in ACLs is pheochromocytoma which secretes catecholamines, and therefore headache, sweating palpitations and hypertension are the most common symptoms. Our case had none of these symptoms and biochemically was negative for pheochromocytoma markers. Pheochromocytomas with negative urine and serum markers are not uncommon 14, 15 . Heavner et al. showed some differences between marker-negative and marker positive patients, including different mean BMI and presentation signs (more vertigo/dizziness in marker-negative patients) 14 . The majority of pheochromocytomas are benign and curable by resection. However, differentiation between benign and malignant pheochromocytoma is one of the most challenging areas in endocrine pathology. Application of pheochromocytoma of the Adrenal Gland Scaled Score (PASS) is one the recent attempts for distinguishing pheochromosytomas with malignant potential, which showed great inter-and intra-observer variation 16 . Immunohistochemical study is a great method in detection of different aspects of diagnosis and treatment [17] [18] [19] [20] [21] [22] [23] . In one study, Saffar et al. examined 55 cases of pheochromocytoma and determined the expression of galectin-3, COX-2, and nm-23 among them 24 . They showed that the presence of these markers along with tumor size and tumor necrosis can be a reasonable predictor of this disease outcome. In another study, Haji Amousha, et al. used the pituitary tumor-transforming gene (PTTG1) to predict malignant behavior of pheochromocytomas 25 . They showed that this IHC marker had 100% specificity and 100% PPV for malignant behavior prediction. Ki67,c-erbB-2 and ckitantigens were also used as predictor markers of tumor behavior in another study by Tavangar et al 19 . Their study demonstrated that these markers could be used to determine the behavior of tumors. The pheochromocytoma part of our case had no metastasis and showed benign behavior.
CONCLUSION
The results of the study highlight the need to increase awareness of rare entities such as ACLs for proper diagnosis of adrenal masses in paraclinical investigations which is critical for staging and treatment.
